Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-28

FDA Approved: QBREXZA — Supplemental Application (Journey Medical Corporation)

View source ↗

Summary

The FDA approved a supplemental application for QBREXZA (glycopyrronium) filed by Journey Medical Corporation. This action updates the product's labeling under …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Qbrexza (glycopyrronium tosylate)

Snippet

SUPPL AP for QBREXZA (GLYCOPYRRONIUM)